Groww Targets Indian Public Markets With Multi-Billion-Dollar IPO Amid Strategic Headquarter Relocation

by THEFUTURE.TEAM

September 19, 2025

Strategic Homecoming Strengthens Market Position

India’s largest retail brokerage, Groww, is gearing up to test the nation’s public markets with a multi-billion-dollar IPO. This milestone follows the company’s strategic decision to re-base its corporate headquarters from Delaware to India, potentially making it the first Indian startup to list domestically after a U.S. relocation.

Major Backing and IPO Dynamics

Endorsed by high-profile investors including Microsoft CEO Satya Nadella, Y Combinator, Ribbit Capital, and Tiger Global, Groww’s IPO is set to deliver significant exit opportunities for global venture funds. According to draft documents, marquee investors are offloading approximately 236 million shares—roughly 5.6% of the company’s equity—making them the largest selling bloc, responsible for about 41% of all public offerings.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Sector-Wide Shift and Comparative Moves

Groww’s homecoming is part of a broader trend among Indian startups. Notable companies like Pine Labs, Razorpay, Meesho, and Zepto have recently relocated back from overseas bases. This shift is paralleled by Walmart-backed PhonePe and Flipkart, both of which have consolidated their operations in India to better align with evolving regulatory frameworks and capitalize on the expanding domestic investor base.

IPO Structure and Financial Highlights

Groww’s upcoming IPO is aimed at raising ₹10.6 billion (approximately $121 million) in fresh funding. Additionally, the secondary sale of 574 million shares by current shareholders is expected to fetch between ₹5–6 billion (roughly $568–$682 million), valuing the Bengaluru-based firm at about $9 billion. Notably, the founders—Lalit Keshre, Harsh Jain, Neeraj Singh, and Ishan Bansal—are divesting only a minimal stake, underscoring their confidence in the company’s long-term vision.

Robust Growth and Market Penetration

Last fiscal, Groww reported a total income of ₹40.6 billion (approximately $462 million), marking a 45% year-on-year increase, despite previous challenges linked to relocation expenses. The firm now boasts 37.4 million individual demat accounts, commanding nearly 19% of India’s market, along with significant traction on key platforms such as the National Stock Exchange.

Conclusion

The convergence of strategic headquarters relocation, robust investor backing, and a thriving domestic market has positioned Groww to leverage India’s increasingly attractive public capital markets. As the firm navigates its IPO, it exemplifies the maturation of the Indian startup ecosystem and reflects a broader trend of companies realigning with home markets to harness emerging opportunities.

The offering is supported by financial giants including JPMorgan Chase, Kotak Mahindra Bank, Citigroup, Axis Bank, and Motilal Oswal Investment Advisors, underscoring the high stakes and serious intent behind this landmark public debut.

The Future Forbes Realty Global Properties

Blood Proteins May Signal Prostate Cancer Risk More Than 15 Years Before Diagnosis

by THEFUTURE.TEAM

October 27, 2026

Distinctive proteins in men’s blood may offer clues to prostate cancer risk more than 15 years before a diagnosis, according to research from the University of Oxford. The findings could help scientists better understand why some prostate cancers become aggressive while others grow slowly and never cause serious harm.

Researchers analyzed blood samples from 2,555 men collected between 1992 and 2000. Of those participants, 982 were later diagnosed with prostate cancer; the remaining 1,573 served as a comparison group. The team measured more than 6,000 proteins in the samples, which had been collected years—and, in some cases, more than 15 years—before diagnosis.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Protein Patterns Were Linked To Different Risks

The analysis identified proteins associated with prostate cancer risk overall, as well as proteins linked specifically to more aggressive or fast-growing forms of the disease. Higher levels of certain immune-system proteins, including GZMK and ANXA2, were associated with a lower long-term risk.

“Finding proteins linked to known prostate cancer driver genes in blood collected years before diagnosis gives us new insights into the earliest stages of the disease,” said Karl Smith-Byrne, the study’s corresponding author at Oxford.

The results, published in European Urology, are significant because prostate cancer is not a single, uniform disease. Many tumors grow slowly and may never threaten a patient’s health, while others progress rapidly and can be life-threatening. A clearer way to distinguish between these outcomes could eventually help improve how clinicians assess risk.

Promising Findings, Not A Screening Test

The researchers stressed that the protein patterns are not ready to be used as a screening test. The associations need further validation before they can inform clinical decisions, and the study does not establish that the proteins cause cancer or that measuring them can predict an individual’s outcome.

“Ultimately, we hope this will help us understand the biology of aggressive prostate cancer and identify markers that could improve how we assess risk in the future,” said first author Zhe Huang, a postdoctoral epidemiologist at Oxford Population Health.

Research Could Point To New Prevention Strategies

Prostate cancer is the most commonly diagnosed cancer among men in the European Union and the second most common worldwide, after lung cancer. In the EU, approximately 330,000 cases are diagnosed and 75,000 men die from the disease each year.

By identifying biological signals that appear long before diagnosis, the research may help scientists investigate the pathways involved in aggressive disease. Smith-Byrne said that, alongside existing and future genetic evidence, the findings could help reveal pathways that might ultimately be targeted to prevent aggressive prostate cancer.

Breaking news